Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,597.47
(
0.63%
)
US TECH 100
23,550.80
(
0.82%
)
Dow Jones
46,458.48
(
0.73%
)
Brent Oil
98.21
(
1.77%
)
Bitcoin
70,799.00
(
0.40%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: go seek post# 12218

Thursday, 06/26/2008 8:06:54 AM

Thursday, June 26, 2008 8:06:54 AM

Post# of 19309
The product name is not the issue. In #msg-30283097 you said:

“i know we have discussed this prior, but what was the major holdup w/ Genzyme Transgenics and use of "Atryn" for HD in earlier P3 trial?”

To which I replied that ATryn was not tested in the HD indication during the “Genzyme Transgenics” days. The phase-3 trial trial you cited in #msg-30280763 was in CABG/HR, not in HD.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today